Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis

Lung Cancer

Volumn 125, Issue , 2018, Pages 212-217

  Yamaguchi, Teppei ^a   Shimizu, Junichi ^a   Hasegawa, Takaaki ^a   Horio, Yoshitsugu ^a   Inaba, Yoshitaka ^a   Yatabe, Yasushi ^a   Hida, Toyoaki ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

Nivolumab; Non small cell lung cancer; PD 1; Pembrolizumab; Pneumonitis

Indexed keywords

ATEZOLIZUMAB; NIVOLUMAB; PEMBROLIZUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; INCIDENCE; JAPAN; LUNG EMPHYSEMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; RADIOLOGIST; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; THORAX RADIOGRAPHY; COMPLICATION; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NIVOLUMAB; PNEUMONIA; PROGRAMMED CELL DEATH 1 RECEPTOR; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 85054447575     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2018.10.001     Document Type: Article

References (37)

1. Daniels, C.E., Jett, J.R., Does interstitial lung disease predispose to lung cancer?. Curr. Opin. Pulm. Med. 11 (2005), 431–437.
2. Raghu, G., Nyberg, F., Morgan, G., The epidemiology of interstitial lung disease and its association with lung cancer. Br. J. Cancer 91:Suppl. (2) (2004), S3–S10.
3. Jung, H.I., Park, J.S., Lee, M.Y., Park, B., Kim, H.J., Park, S.H., Choi, W.I., Lee, C.W., Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease. Medicine (Baltim.), 97, 2018, e0071.
4. Kudoh, S., Kato, H., Nishiwaki, Y., Fukuoka, M., Nakata, K., Ichinose, Y., Tsuboi, M., Yokota, S., Nakagawa, K., Suga, M., Japan Thoracic Radiology Group, Jiang, H., Itoh, Y., Armour, A., Watkins, C., Higenbottam, T., Nyberg, F., Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am. J. Respir. Crit. Care Med. 177 (2008), 1348–1357.
5. Niho, S., Goto, K., Yoh, K., Kim, Y.H., Ohmatsu, H., Kubota, K., Saijo, N., Nishiwaki, Y., Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs. Jpn. J. Clin. Oncol. 36 (2006), 269–273.
6. Isobe, K., Hata, Y., Sakamoto, S., Takai, Y., Shibuya, K., Homma, S., Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy. Respirology 15 (2010), 88–92.
7. Minegishi, Y., Takenaka, K., Mizutani, H., Sudoh, J., Noro, R., Okano, T., Azuma, A., Yoshimura, A., Ando, M., Tsuboi, E., Kudoh, S., Gemma, A., Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy. Intern. Med. 48 (2009), 665–672.
8. Tsujino, K., Hashimoto, T., Shimada, T., Yoden, E., Fujii, O., Ota, Y., Satouchi, M., Negoro, S., Adachi, S., Soejima, T., Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer. J. Thorac. Oncol. 9 (2014), 983–990.
9. Wong, R.M., Scotland, R.R., Lau, R.L., Wang, C., Korman, A.J., Kast, W.M., Weber, J.S., Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int. Immunol. 19 (2007), 1223–1234.
10. Hamid, O., Robert, C., Daud, A., Hodi, F.S., Hwu, W.J., Kefford, R., Wolchok, J.D., Hersey, P., Joseph, R.W., Weber, J.S., Dronca, R., Gangadhar, T.C., Patnaik, A., Zarour, H., Joshua, A.M., Gergich, K., Elassaiss-Schaap, J., Algazi, A., Mateus, C., Boasberg, P., Tumeh, P.C., Chmielowski, B., Ebbinghaus, S.W., Li, X.N., Kang, S.P., Ribas, A., Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369 (2013), 134–144.
11. Brahmer, J., Reckamp, K.L., Baas, P., Crinò, L., Eberhardt, W.E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E.E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M.C., Aerts, J.G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C.T., Lestini, B., Spigel, D.R., Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 123–135.
12. Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D.R., Steins, M., Ready, N.E., Chow, L.Q., Vokes, E.E., Felip, E., Holgado, E., Barlesi, F., Kohlhäufl, M., Arrieta, O., Burgio, M.A., Fayette, J., Lena, H., Poddubskaya, E., Gerber, D.E., Gettinger, S.N., Rudin, C.M., Rizvi, N., Crinò, L., Blumenschein, G.R. Jr., Antonia, S.J., Dorange, C., Harbison, C.T., Graf Finckenstein, F., Brahmer, J.R., Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 373 (2015), 1627–1639.
13. Herbst, R.S., Baas, P., Kim, D.W., Felip, E., Pérez-Gracia, J.L., Han, J.Y., Molina, J., Kim, J.H., Arvis, C.D., Ahn, M.J., Majem, M., Fidler, M.J., de Castro, G. Jr., Garrido, M., Lubiniecki, G.M., Shentu, Y., Im, E., Dolled-Filhart, M., Garon, E.B., Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387 (2016), 1540–1550.
14. Reck, M., Rodríguez-Abreu, D., Robinson, A.G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., O'Brien, M., Rao, S., Hotta, K., Leiby, M.A., Lubiniecki, G.M., Shentu, Y., Rangwala, R., Brahmer, J.R., KEYNOTE-024 Investigators, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375 (2016), 1823–1833.
15. Kazerooni, E.A., Martinez, F.J., Flint, A., Jamadar, D.A., Gross, B.H., Spizarny, D.L., Cascade, P.N., Whyte, R.I., Lynch, J.P. 3rd, Toews, G., Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring. AJR Am. J. Roentgenol. 169 (1997), 977–983.
16. Raghu, G., Collard, H.R., Egan, J.J., Martinez, F.J., Behr, J., Brown, K.K., Colby, T.V., Cordier, J.F., Flaherty, K.R., Lasky, J.A., Lynch, D.A., Ryu, J.H., Swigris, J.J., Wells, A.U., Ancochea, J., Bouros, D., Carvalho, C., Costabel, U., Ebina, M., Hansell, D.M., Johkoh, T., Kim, D.S., King, T.E. Jr., Kondoh, Y., Myers, J., Müller, N.L., Nicholson, A.G., Richeldi, L., Selman, M., Dudden, R.F., Griss, B.S., Protzko, S.L., Schünemann, H.J., ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis, an official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183 (2011), 788–824.
17. Satoh, K., Kobayashi, T., Misao, T., Hitani, Y., Yamamoto, Y., Nishiyama, Y., Ohkawa, M., CT assessment of subtypes of pulmonary emphysema in smokers. Chest 120 (2001), 725–729.
18. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services, National Institute of Health National Cancer Institute. Available at https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on 15 September 2018).
19. Omori, T., Tajiri, M., Baba, T., Ogura, T., Iwasawa, T., Okudela, K., Takemura, T., Oba, M.S., Maehara, T., Nakayama, H., Tsuboi, M., Masuda, M., Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann. Thorac. Surg. 100 (2015), 954–960.
20. Fujimoto, D., Morimoto, T., Ito, J., Sato, Y., Ito, M., Teraoka, S., Otsuka, K., Nagata, K., Nakagawa, A., Tomii, K., A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer 111 (2017), 1–5.
21. Kato, T., Masuda, N., Nakanishi, Y., Takahashi, M., Hida, T., Sakai, H., Atagi, S., Fujita, S., Tanaka, H., Takeda, K., Satouchi, M., Namba, Y., Tamura, T., Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer. Lung Cancer 104 (2017), 111–118.
22. Nakano, Y., Muro, S., Sakai, H., Hirai, T., Chin, K., Tsukino, M., Nishimura, K., Itoh, H., Paré, P.D., Hogg, J.C., Mishima, M., Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function. Am. J. Respir. Crit. Care Med. 162 (2000), 1102–1108.
23. Xaubet, A., Agustí, C., Luburich, P., Roca, J., Montón, C., Ayuso, M.C., Barberá, J.A., Rodriguez-Roisin, R., Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 158 (1998), 431–436.
24. Naidoo, J., Wang, X., Woo, K.M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J.E., Segal, N.H., Callahan, M.K., Lesokhin, A.M., Rosenberg, J., Voss, M.H., Rudin, C.M., Rizvi, H., Hou, X., Rodriguez, K., Albano, M., Gordon, R.A., Leduc, C., Rekhtman, N., Harris, B., Menzies, A.M., Guminski, A.D., Carlino, M.S., Kong, B.Y., Wolchok, J.D., Postow, M.A., Long, G.V., Hellmann, M.D., Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J. Clin. Oncol. 35 (2017), 709–717.
25. SanlorenzoM, Vujic I., Daud, A., Algazi, Gubens M., Luna, S.A., Lin, K., Quaglino, P., Rappersberger, K., Ortiz-Urda, S., Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 151 (2015), 1206–1212.
26. Nakamura, Y., Tanaka, R., Asami, Y., Teramoto, Y., Imamura, T., Sato, S., Maruyama, H., Fujisawa, Y., Matsuya, T., Fujimoto, M., Yamamoto, A., Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study. J. Dermatol. 44 (2016), 117–122.
27. Haratani, K., Hayashi, H., Chiba, Y., Kudo, K., Yonesaka, K., Kato, R., Kaneda, H., Hasegawa, Y., Tanaka, K., Takeda, M., Nakagawa, K., Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer. JAMA Oncol. 4 (2018), 374–378.
28. Sato, K., Akamatsu, H., Murakami, E., Sasaki, S., Kanai, K., Hayata, A., Tokudome, N., Akamatsu, K., Koh, Y., Ueda, H., Nakanishi, M., Yamamoto, N., Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115 (2018), 71–74.
29. Murashige, N., Tanimoto, T., Oshima, Y., Interstitial lung disease and gefitinib. N. Engl. J. Med. 363 (2010), 1578–1579.
30. Kim, J.H., Kim, H.S., Kim, B.J., Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Oncotarget 8 (2017), 93149–93155.
31. Wang, P.F., Chen, Y., Song, S.Y., Wang, T.J., Ji, W.J., Li, S.W., Liu, N., Yan, C.X., Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front. Pharmacol., 8, 2017, 730.
32. Nishino, M., Giobbie-Hurder, A., Hatabu, H., Ramaiya, N.H., Hodi, F.S., Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis. JAMA Oncol. 2 (2016), 1607–1616.
33. Takada, K., Okamoto, T., Shoji, F., Shimokawa, M., Akamine, T., Takamori, S., Katsura, M., Suzuki, Y., Fujishita, T., Toyokawa, G., Morodomi, Y., Okano, S., Oda, Y., Maehara, Y., Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J. Thorac. Oncol. 11 (2016), 1879–1890.
34. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., Carcereny, E., Ahn, M.J., Felip, E., Lee, J.S., Hellmann, M.D., Hamid, O., Goldman, J.W., Soria, J.C., Dolled-Filhart, M., Rutledge, R.Z., Zhang, J., Lunceford, J.K., Rangwala, R., Lubiniecki, G.M., Roach, C., Emancipator, K., Gandhi, L., KEYNOTE-001 Investigators, Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
35. Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N.D., Kanchi, K.L., Maher, C.A., Fulton, R., Fulton, L., Wallis, J., Chen, K., Walker, J., McDonald, S., Bose, R., Ornitz, D., Xiong, D., You, M., Dooling, D.J., Watson, M., Mardis, E.R., Wilson, R.K., Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell 150 (2012), 1121–1134.
36. Carbone, D.P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M.M., Ciuleanu, T.E., Badin, F., Ready, N., Hiltermann, T.J.N., Nair, S., Juergens, R., Peters, S., Minenza, E., Wrangle, J.M., Rodriguez-Abreu, D., Borghaei, H., Blumenschein, G.R. Jr., Villaruz, L.C., Havel, L., Krejci, J., Corral Jaime, J., Chang, H., Geese, W.J., Bhagavatheeswaran, P., Chen, A.C., Socinski, M.A., CheckMate 026 Investigators, First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N. Engl. J. Med. 376 (2017), 2415–2426.
37. Hida, T., Kaji, R., Satouchi, M., Ikeda, N., Horiike, A., Nokihara, H., Seto, T., Kawakami, T., Nakagawa, S., Kubo, T., Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study. Clin. Lung Cancer 19 (2018), e405–e415.